Redox Status ofβ2GPI in Different Stages of Diabetic Angiopathy.
We explored the redox status of beta 2 glycoprotein I (β2GPI) in different stages of diabetic angiopathy. Type 2 diabetes mellitus (T2DM) had a significantly lower proportion of reducedβ2GPI as compared to healthy controls (p< 0.05). There was a trend that the mild coronal atherosclerosis heart disease (CAD) had higher proportion of reducedβ2GPI than non-CAD and severe-CAD groups, however without significances (p> 0.05). The mild-A-stenosis group and mild-diabetic retinopathy (DR) groups had higher proportion of reducedβ2GPI than their severely affected counterparts. The mild-slow nerve conduction velocity (NCVS) group had higher proportion of reducedβ2GPI than normal nerve conduction velocity (NCVN group) and severe-NCVS groups. The proportion of reducedβ2GPI was in positive correlation with 24 h urine microalbumin and total urine protein, and the proportion of reducedβ2GPI was in negative correlation with serum and skin advanced glycation end products (AGEs). Taken together, our data implicate that the proportion of reducedβ2GPI increased in the early stage of angiopathy and decreased with the aggravation of angiopathy.
Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China.
Jun
J
Ma
Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China.
Jing-Yun
JY
Zhang
Tianjin Haibin People's Hospital, Tianjin, China.
Yan
Y
Liu
Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China.
De-Min
0000-0001-7658-9200
DM
Yu
Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China.
Pei
0000-0001-6137-5824
P
Yu
D015415:Biomarkers / Q000378:metabolism*; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications*; D009367:Neoplasm Staging; D010084:Oxidation-Reduction; D011379:Prognosis; D053482:beta 2-Glycoprotein I / Q000378:metabolism*
D015415:Biomarkers; D053482:beta 2-Glycoprotein I